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1, interleukin 1 beta and interferon gamma:
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Abstract
Background: IgG4-related disease often forms a mass and the affected lesion is clinically removed because the
mass cannot be differentiated from a neoplasm. Affected lesions commonly occur in the pancreas, hepatobiliary
tract, kidney, and retroperitoneum. However, the lesion rarely occurs in the thymus. A histological worldwide
consensus of IgG4-related disease proposed that pathological diagnosis of IgG4-related disease should meet more
than two of three major features: 1) dense lymphoplasmacytic infiltration with greater than 40% IgG4+/IgG+
plasma cells, 2) storiform fibrosis; and 3) obliterative phlebitis. Currently, fibrosis of IgG4-related disease is thought to
be induced by profibrotic cytokines such as transforming growth factor beta 1 (TGFB1), interleukin 1 beta (IL1B) and
interferon gamma (IFNG), which are secreted by regulatory T cells (Tregs) and CD4-positive cytotoxic T cells.
However, it is unclear whether profibrotic cytokines are associated with the fibrosis seen in IgG4-related thymitis.
Here we examined whether cytokines in the mass were increased compared with those in the surrounding thymus,
and whether Tregs were present in the mass, using reverse transcription absolute quantitative polymerase chain
reaction (RT-ab-qPCR) and immunohistochemistry.
Case presentation: A 70-year-old Japanese man contracted IgG4-letated thymitis. Histological and
immunohistochemical analyses demonstrated his mass had massive fibrosis with a focally storiform pattern and
lymphoplasmacytic infiltration with 40% IgG4+/IgG+ plasma cells, but not obliterative phlebitis. The mass was
surrounded by atrophic thymus. We diagnosed the mass as IgG4-related thymitis. Immunohistochemically, Tregs
were scattered throughout the mass. RT-ab-qPCR showed that messenger RNA expressions of TGFB1, IL1B and IFNG
in the mass were 270-, 158- and 5.5- fold higher than in the surrounding thymus. His serum IgG4 level after surgery
was within the normal range (83.4 mg/dl soon after surgery, 89.3 mg/dl 2 weeks after surgery).
Conclusions: Our results suggested the profibrotic cytokines TGFB1, IL1B and IFNG induce fibrosis and that Tregs
might produce some of these cytokines in IgG4-related thymitis as well as in the other affected lesions of IgG4-
related disease.
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Background
Sclerosing mediastinitis is a rare disorder and results
from many etiologies, e.g. infection, sarcoidosis, radi-
ation and autoimmune conditions [1]. A few cases of
sclerosing mediastinitis were reported to be IgG4-
related diseases [2–4]. IgG4-related disease shows
storiform fibrosis with IgG4-positive plasma cell-rich
lymphoplasmacytic infiltrates by histological and im-
munohistochemical analysis, but high IgG4 levels are
not always present in patient sera [4]. IgG4-related
mass-forming diseases occur at any site in the body
such as the pancreas, biliary duct, salivary gland, kid-
ney, thyroid, aorta, retroperitoneum and mediastinum
[4–6]. The masses are clinically recognized and re-
moved as neoplasms [6]. In 2011, IgG4-related disease
experts developed IgG4-related disease diagnostic cri-
teria, in which pathological diagnosis of IgG4-related
disease requires more than two of three major fea-
tures: 1) dense lymphoplasmacytic infiltration with
greater than 40% IgG4+/IgG+ plasma cells; 2) at
least focally arranged storiform fibrosis; and 3)
obliterative phlebitis [4]. Recently, Umehara et al.
proposed comprehensive diagnostic criteria of IgG4-
related disease. According to their new criteria, diag-
nosis requires the following three condition: 1) organ
involvement; 2) > 135 mg/dl IgG in patient serum;
and 3) > 40% IgG4+/IgG+ plasma cells in the af-
fected organ [7]. They also reported that serum IgG4
levels are not specific, and that histopathological fea-
tures are a more specific and important hallmarks of
IgG4-related disease [7].
Recent studies have examined the mechanisms through
which fibrosis occurs in IgG4-related diseases of the
salivary gland, hepato-bilio-pancreatic systems and kidney
[7–10]. They speculated that regulatory T cells (Tregs) se-
creting transforming growth factor beta 1 (TGFB1) in
IgG4-related lesions cause mass-forming fibrosis. FoxP3 is
a specific marker of Tregs, and two subsets of Tregs se-
crete TGFB1 and one subset secretes interferon-gamma
(IFNG) [11]. Recently, CD4-positive cytotoxic T cells
(CTLs), which do not have a specific marker [12], were
expanded in the affected lesion of IgG4-related disease of
the pancreas, salivary glands, orbit, lymph node, retroperi-
toneum, kidney and lung [13–16] and secreted the
profibrotic cytokines TGFB, interleukin 1 beta (IL1B) and
IFNG [12]. However, it is unclear which mechanisms are
involved in the fibrosis of IgG4-related sclerosing
mediastinitis.
We experienced a case histopathologically consistent
with IgG4-related thymitis, which occurred in a thy-
mus of a 70-year-old Japanese man. We assumed that
fibrosis of the IgG4-related lesion might be caused by
the same mechanism involved in IgG4-related disease
of previously examined organs. We evaluated whether
Tregs were present and whether TGB1, IL1B and
IFNG were increased in the mass of our case using
immunohistochemical analysis of FoxP3, and reverse
transcription- absolute quantitative polymerase chain
reaction (RT- ab-qPCR) for TGB1, IL1B and IFNG
messenger RNAs (mRNAs) from paraffin-embedded
specimens of our case.
Case presentation
A 70-year-old Japanese man was admitted to our hos-
pital because of mediastinal mass found during a rou-
tine health examination. He had also suffered from
diabetes mellitus, but the disease was fully controlled
through medication. Computed tomography (CT)
scanning revealed a solid mass measuring 3 cm in the
maximum diameter, located adjacent to the left side
of the left pulmonary artery. Small calcification was
found in the mass (Fig. 1a). Preoperative examination
revealed no extra-mediastinal manifestation. We clin-
ically suspected the mass might be a thymoma, and
decided to remove the mass. Preoperative examination
of his blood and serum detected no abnormal data,
although IgG4 was not tested. He did not receive
blood transfusion for operation and his loss of blood
during operation was 28 ml. His serum was collected
soon after surgery and contained 83.4 mg/dl of IgG4
(normal range: 4.8–105 mg/dl) and 1343 mg/dl of
IgG (normal range: 800–1700 mg/dl), and IgG frac-
tionation was within the normal range.
The resected specimen was macroscopically a solid
and fibrous mass surrounded by fatty tissue (Fig. 1b).
Sections showed a whitish and fibrous mass located in
the center of the specimen. The mass seemed to be
lobular but with no obvious fibrous septa (Fig. 1c).
Hematoxylin and eosin staining analyzed with a
loupe showed a pinkish mass surrounded by mature
fat tissue (Fig. 2a). Calcification was observed in the
mass. Microscopically, the solid mass was composed
of dense collagen, fibroblast-like spindle cells, some
of which had a large nucleus, and inflammatory
cells. No capsulation was seen. Fibroblast-like cells
formed a storiform pattern (Fig. 2b), and hyalinized
stroma was focal. The inflammatory cells included
many small lymphocytes and plasma cells but few
eosinophils. The lymphocytes and plasma cells had
tendency to aggregate (Fig. 2c), while eosinophils
were scattered throughout the mass. There were
some plasmablasts, which had immature nuclei with
some nucleoli and a narrow perinuclear halo, in the
lymphoplasmacytic aggregates. There was no lym-
phoplasmacytic obliterative phlebitis in the mass by
the Elastica van Gieson staining analysis. The histo-
logical findings indicated the differential diagnosis of
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IgG4-related disease, sclerosing thymoma, a solitary
fibrous tumor and an inflammatory myofibroblastic
tumor [17–19].
Immunohistochemical analyses were performed on
paraffin-embedded materials using Bond-Max autostai-
ner (Leica Biosystems Melbourne Pty, Ltd., Melbourne,
Victoria, Australia). The mass was negative for keratin,
signal transducer and activator of transcription 6
(STAT6), desmin, smooth muscle actin and anaplastic
lymphoma kinase (ALK), and there were no terminal
deoxynucleotidyl transferase (TdT)-positive immature
lymphocytes in the mass. We did not consider the mass
as a thymic epithelial tumor such as a thymoma, a soli-
tary fibrous tumor and an inflammatory myofibroblastic
tumor accordingly. Almost two thirds of plasma cells
were positive for IgG and the mean percentage of IgG-
positive plasma cells counted in three × 400 high power
fields containing the highest number of IgG4 plasma
cells was 40% (Fig. 2d and e). The surrounding fatty tis-
sue contained aggregates of small lymphocytes that were
positive for CD3, CD1a and TdT, and that were trapped
in keratin-positive meshworks. Consistently, we ob-
served that the surrounding tissue around the mass was
an atrophic thymus. According to the histological
criteria of IgG4-related disease reported by Deshpande
et al. [4], we histopathologically diagnosed the mass as
IgG4-related thymitis because the lesion was located in
the thymus. Next, immunohistochemically analysis of
FoxP3 demonstrated Tregs were scattered throughout
the mass (Fig. 2f ). We purchased antibodies or anti-
serum against keratin (clone AE1 and AE3), desmin,
smooth muscle actin, CD3, CD1a, TdT and ALK from
Leica Biosystems Newcastle Ltd. (Newcastle upon Tyne,
UK), against IgG4 from The Binding Site Ltd. (Birmingham,
UK), against STAT6 from Santa Cruz Biotechnology, Inc.
(Dallas, TX, USA) and against FoxP3 from Cell Signaling
Technology (Danvers, MA, USA).
We used RT- ab-qPCR to compare the relative copy
numbers of TGFB1, IL1B and IFNG mRNAs to TATA
box-binding protein (TBP) mRNA of the mass with those
of the surrounding thymus. We isolated total RNA from
paraffin-embedded specimens of the mass and the
surrounding thymus, using a miRNeasy FFPE Microkit
(Qiagen GmbH, Hilden, Germany). Then, the isolated
RNAs were reverse-transcribed using PrimeScript II first
strand cDNA Synthesis Kit (Takara Bio Inc., Kusatsu,
Shiga, Japan). RT-ab-qPCR primer pair for TBP mRNA
was the same as previously reported [20], and primer pairs
for TGFB1, IL1B and IFNG mRNAs for RT-ab-qPCR were
generated according to National Center for Biotechnology
Information (NCBI) reference sequences NM_000660.6,
NM_000576.2, and NM_000619.2, respectively. The pri-
mer pairs are listed in Table 1.We carried out quantita-
tive PCR using the SYBR Green intercalation method
with Illumina Eco (San Diego, CA, USA). We con-
firmed the specificity of every primer pair, seeing one
sharp peak on a dissociation curve. The relative ex-
pression level of TGFB1 mRNA to TBP mRNA of the
mass was 16.2, whereas that of the surrounding thy-
mus was 0.06. The relative expression level of IL1B
mRNA to TBP mRNA of the mass was 696.3,
whereas that of the surrounding thymus was 4.4. The
relative expression level of IFNG mRNA to TBP
mRNA of the mass was 79.2, whereas that of the sur-
rounding thymus was 14.5. TGB1, IL1B and IFNG
mRNA expression levels of the mass was 270-, 158-
Fig. 1 Computed tomography scanning and the removed specimen. a Preoperative computed tomography revealed a mass adjacent to the left
side of the left pulmonary artery (arrow). However, there was a thin line between the mass and the pulmonary artery. b The resected specimen
with one section showed a solitary mass surrounded by fat tissue. c The cut section: the mass was lobular but with no obvious fibrous septa
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and 5.5- fold higher than those of the surrounding
thymus, respectively.
Two weeks after surgery, the serum IgG4 of the pa-
tient was 89.3 mg/dl and the IgG was 1490 mg/dl. Frac-
tionation of IgG was within the normal range. He was
doing well 2 months after surgery.
Discussion and conclusions
We experienced a rare case of IgG4-related thymitis. In
a broad sense, this case is included in sclerosing medias-
tinitis, because the thymus is located in the anterior
mediastinum. However, it is uncertain whether, in the
reported cases, the IgG4-related sclerosing mediastinitis
occurred in the thymus or not. Our case is thought to
be a first case in which IgG4-related lesions undoubtedly
occurred in the thymus. Although our patient did not
present high IgG4 in his serum, we diagnosed the mass
as IgG4-related disease according to a worldwide histo-
pathological consensus reported by Deshpande et al. [4].
IgG4-related disease forms a mass with a focally or
diffusely storiform fibrosis, and the masses are often re-
moved because they are clinically recognized as neo-
plasms. Umehara et al. recently proposed comprehensive
criteria of IgG4-related disorders [7]. According to their
new comprehensive criteria, a definitive diagnosis of
IgG4-related disease that occurs outside the pancreas,
the bile duct, the kidney, the respiratory systems and the
ophthalmic systems, should be made in the patients with
three conditions: organ involvement, high serum IgG4
(> 135 mg/dl) and histological features as IgG4 + plasma
Fig. 2 Pathological images with hematoxylin and eosin staining and immunohistochemical staining. a A fibrous tumor with inflammatory cells and two
foci of calcification. (hematoxylin and eosin (HE), loupe). b High magnification view of the tumor shows storiform pattern by fibroblast-like cells. (HE, × 200
magnification). c Inflammatory cell aggregates were composed of small lymphocytes and plasma cells (HE, × 200 magnification). d IgG-positive plasma cells
were located in the inflammatory cell aggregates. (× 400 magnification). e Forty percent of IgG-positive plasma cells expressed IgG4. (× 400 magnification).
f Tregs, which express FoxP3, were scattered throughout the mass. (× 200 magnification)
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cells > 10/high power field and IgG4+/IgG+ cells > 40%
in the affected lesion. However, they showed reported
IgG4-related cases which had occurred in the skin, the
retroperitoneum and the prostate did not present high
serum IgG4. There are reported a few cases of IgG4-
related sclerosing mediastinitis/thymitis. Inoue et al. re-
ported a case of IgG4-related mediastinitis and that their
patient, whose IgG4 of the serum was 127 mg/dl, had
been successfully treated with prednisolone. It is uncer-
tain whether the recent criteria of IgG4-related disease
proposed by Umehara et al. can be applicable for IgG4-
related sclerosing mediastinitis/thymitis or not.
Moreover, Fox and Fox reviewed that elevated IgG4
levels in the serum was no longer a surrogate marker fot
IgG4-related disease [21], and Wallace et al. reported
that elevated counts of circulating plasmablasts were a
useful biomarker for diagnosis of IgG4-related disease,
even in patients with normal serum IgpG4 concentra-
tions [22]. We did not examine the circulating plasma-
blasts counts before operation. Therefore, we regarded
the worldwide histological consensus of IgG4-related
disease more important than the recent criteria of IgG4-
related disease.
Currently, the profibrotic cytokines TGFB1, IL1B and
IFNG secreted by Tregs and CD4-positive CTLs are
thought to induce fibrosis in IgG4-related disease in
hepato-bilio-pancreatic systems, salivary glands, retro-
peritoneum, kidney and lung [8–10, 12–15]. However, it
is unclear which mechanisms are involved in the forma-
tion of the fibrous mass in IgG4-related thymitis. Here
we examined whether Tregs and profibrotic cytokines
are associated with the fibrosis of IgG4-related thymitis.
We did not evaluate CD4-positive CTLs from this exam-
ination because a specific marker for CD4-positive CTLs
has not been identified [12]. Our immunohistochemical
analysis of Tregs, using antibody against FoxP3, a
specific marker of Tregs, showed scattered Tregs
throughout the mass. The existence of Tregs in the mass
suggested they might secrete profibrotic cytokines. RT-
ab-qPCR demonstrated the higher expression of TGFB1,
IL1B and IFNG mRNAs in the affected mass compared
with the surrounding thymus suggesting Tregs secrete pro-
fibrotic cytokines. To confirm the increase in profibrotic cy-
tokines in the mass, the amount of profibrotic cytokine
proteins extracted from fresh or snap-frozen tissues in the
mass should be compared to those in the surrounding
thymus. However, we did not take fresh material from the
thymus although we saved snap-frozen material from the
mass. Consequently, we measured the profibrotic cytokine
mRNA expressions. Although epigenetic modification
occurs post-transcriptionally [23], our results indicated that
profibrotic cytokines might be increased in the mass and
related to fibrosis as well as fibrosis of IgG4-related disease
in organs other than the thymus.
We did not assess CD4-positive CTLs in the mass.
However, increased IL1B mRNA in the mass might indicate
the presence of CD4-positive CTLs in the mass, because
CD4-positive CTLs in previously examined lesions of IgG4-
related disease were reported to secrete TGFB1, IL1B and
IFNG that induced fibrosis [12–15].
In conclusion, we showed that increased profibrotic
cytokines, TGFB1, IL1B and IFNG might induce fibrosis
in the affected lesion of IgG4-related thymitis. However,
future studies of fibrosis of IgG4-related thymitis should
measure cytokine proteins and ensure that Tregs as well
as CD4-positive CTLs isolated from the affected lesion
can produce the cytokines and induce fibrosis in vivo
and/or in vitro.
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